# CD19/BCMA CAR-T Cell Therapy for Refractory/Relapsed Lupus Nephritis

> **NCT06785519** · EARLY_PHASE1 · RECRUITING · sponsor: **He Huang** · enrollment: 9 (estimated)

## Conditions studied

- Lupus Nephritis

## Interventions

- **BIOLOGICAL:** CD19/BCMA Lupus Nephritis Targeted CAR T-cells injection

## Key facts

- **NCT ID:** NCT06785519
- **Lead sponsor:** He Huang
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-31
- **Primary completion:** 2027-10-31
- **Final completion:** 2027-10-31
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2025-01-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06785519

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06785519, "CD19/BCMA CAR-T Cell Therapy for Refractory/Relapsed Lupus Nephritis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06785519. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*